As China Volume Purchase Builds, Novartis Scrambles To Launch New Products
The Largest VBP Looming
China’s latest volume-based purchase round is also the largest ever, covering more drugs and many of them are the widest-prescribed products. Novartis feels the pinch of price pressures but emphasizes a shift to new product launches.
